Date: July 28, 2003 Label No. EV306611732US

I hereby certify that, on the date indicated above, I deposited this paper with identified attachments and/or fee with the U.S. Postal Service and that it was addressed for delivery to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 by "Express Mail Post Office to Addressee" service.

Name (Print)

ASNUT Signature

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: Beppino C. GIOVANELLA et al.)	
Application No.: Unassigned)	Docket No. 3603-030-03
Filed: July 28, 2003)	Parent Examiner: Goldberg, J.
Parent Group Art Unit: 1614)	Confirmation No.: Unassigned

For: A METHOD FOR TREATING CANCER WITH WATER-INSOLUBLE S-CAMPTOTHECIN OF THE

CLOSED LACTONE RING FORM AND DERIVATIVES THEREOF

INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

July 28, 2003

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. Except for U.S. Patent No. 6,342,506 B1, which is enclosed, the remaining documents were cited in §120 related U.S. Patent Application No. 10/052,294 filed January 18, 2002; U.S. Patent Application No. 09/080,722 filed May 21, 1998; U.S. Patent Application No. 08/767,861 filed December 17, 1996; U.S. Patent Application No. 08/713,392 filed September 13, 1996; U.S. Patent Application No. 08/474,761 filed June 7, 1995; U.S. Patent Application No. 08/301,727 filed September 7, 1994; U.S. Patent Application No. 08/002,244 filed January 15, 1993; U.S. Patent Application No. 07/820,334 filed January 14, 1992; and/or U.S. Application No. 07/432,066 filed November 6, 1989, for which the applicants rely for the benefits provided in 35 U.S.C. § 120. In accordance with M.P.E.P. § 609, it is not necessary to provide copies of those documents with this filing.

Information Disclosure Statement U.S. Patent Application No. Unassigned

This Information Disclosure Statement is being submitted before expiration of the three-

month period following filing of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first

instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and

1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully

requested that the information be expressly considered during the prosecution of this application,

and that the documents cited in the attached Form PTO-1449 be made of record therein and appear

on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists

and does not constitute an admission that each or all of the listed documents are material or

constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in

this application and applicant determines that the cited documents do not constitute "prior art" under

United States law, applicant reserves the right to present to the office the relevant facts and law

regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of

the disclosed invention over the listed documents, should one or more of the documents be applied

against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it

is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any

fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,

Luke A. Kilyk

Reg. No. 33,251

Atty. Docket No.: 3603-030-03

KILYK & BOWERSOX, P.L.L.C.

53 A East Lee Street

Warrenton, VA 20186

Tel: (540) 428-1701

Fax: (540) 428-1720

Enclosures: PTO-1449 w/ 1 document

Atty. Docket No.: 3603-030-02				Application No	.:	To Be Assigned		
Applicant:	GIOVANELL	A et al.	•		-			
Filing Date:	July 28, 200	3	1	Parent Group Art	Unit:	1614	· · · · · ·	
			U.S	. PATENT DO	OCUMI	ENTS		
Examiner Initial*	Docum Numb		•	Name		Class	Sub Class	Filing Date If Appropriate
	5,552,154	9/3/96	Gie	ovanella, et al.	Î	424	449	
	5,652,244	7/29/97	Gi	ovanella, et al.		424	449	
	5,889,017	3/30/99	Gio	ovanella, et al.		514	283	
	6,080,751	6/27/20	00 Ste	ehlin, et al.		514	283	
	6,166,029	12/26/2	000 Gi	ovanella, et al.		514	283	
	6,342,506	1/29/02	Gi	ovanella et al.		514	283	
			FORE	IGN PATENT	DOCU	MENTS		
	Docum Numb		te	Country		Class	Sub Class	Translation Yes or No
						_		
		OTHER DOCUM	ENTS (In	ncluding Autho	or, Title	e, Date, P	ertinent Pages, E	tc.)
Examiner					Date C	Considered		
*Examiner:	Initial if refe conformance	rence considered, ve and not considere	whether or d. Include	not citation is in copy of this for	n confor rm with	mance wit	th MPEP 609; draw munication to appli	v line through citation if not in cant.
Form PTO 144	19					Patent and	I Trademark Office	e - U.S. Department of Commerce

· <u>.</u>.

Arty. Docket No.: 3603-030-03 Applic				cation No.: To be Assigned						
Applicant:	Giovan	ella, e	t al.		L		 _			
Filing Date:	July	28,	2003 P	2003 ParentGroup Art Unit: 1614						
			U	S. PA	TENT	DOCUMENT	S			
Examiner	Initial*		Document Number	D	ate	Nan	ne .	Class	Sub Class	Filing Date
			RE 32,518	10/1	3/87	Miyasaka et	al.			
			3,894,029	07/0	08/75	Winterfeldt e	et al.			
			4,031,098	06/2	21/77	Sugasawa				
			4,357,422	11/0	02/82	Giard et al.				
			4,399,276	08/	16/83	Miyasaka et	al.			
			4,399,282	08/16/83		Miyasaka et al.				
		4,473,692	097.	09/25/84 Miyasaka et al.		al.				
			4,513,138	04/	23/85	Miyasaka et	al.			
		4,545,880	10/	08/85	Miyasaka et	al.				
			4,604,463	08/05/86		Miyasaka et al. Cook et al.				
			4,774,236							
	······································		4,867,978	09/	19/89	Gold				
			4,874,779	10/	17/89	Senter				
			4,894,456	01/	16/90	Wall et al.				
			4,904,768	02/	27/90	Saulnier et	al.			
			4,914,205	04/	03/90	Sawada et	al.			
-			4,939,255	07/	03/90	Tagawa et	al.			
•			4,943,579	07.	24/90	Vishnuvajja	ala et al.			
			4,981,968	01.	/01/91	Wall et al				
,			5,004,758	04	/02/91	Boehm et	a:			

	5,041,424	08/20/91	Saulnier et al.			
	5,049,668	09/17/91	Wall et al.			
	5,053,512	10/01/91	Wani et al.			
	5,061,795	10/29/91	Tagawa et al.			
	5,061,800	10/29/91	Yaegashi et al.			
	5,064,823	11/12/91	Lee et al.			
	5,106,742	04/21/92	Wall et al.			
	5,122,526	06/16/92	Wall et al.			
	5,122,606	06/16/92	Wani et al.			
	5,126,351	06/30/92	Luzzio et al.			
	5,145,684	09/08/92	Liversidge et al.			
	5,155,225	10/13/92	Fortunak et al.			
	5,162,532	11/10/92	Comins et al.			
	5.180,722	01/19/93	Wall et al.			
·	5,225,404	07/06/93	Giovanella et al.			
	FOR	EIGN PATE	NT DOCUMENTS			
	Document Number	Date	Country	Class	Sub Class	Translation Yes or No
	59-501288	03/24/84	Japan			
	61-85389	04/30/86	Japan			-
	61-85319	04/30/86	Japan			
	61-50985	03/13/83	Japan			
	59-51289	03/24/84	Japan			
	59-5188	01/12/84	Japan			
	0 220 601	05/06/87	EPO			
	- · ·				 	
	0 074 256	03/16/83	EPO			
		03/16/83	EPO PCT			
	0 074 256	 -	 			

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	1992 AACR Abstract Form, "Pharmacokinetics of Tritum Labeled Camptothecin in Nude Mice," Smith, P.L. et al.
	1992 AACR Abstract Form, "Growth Inhibition of Human Cancer Metasteses in the Xenograft Model by Camptothecin [NSC 94600], 9-amino-(NSC 60371] and 9-nitrocamptothecin," Potmesil, M.
	Giovanella et al., Cancer Research, Vol. 51, pp. 3052-3055, June 1, 1991
T- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1- 1-	Kharbanda et al., Cancer Research, Vol. 51, pp. 6636-6642, December 15, 1991
·	The Alkaloids, Vol. XXV, Chapter 1, "Antitumor Alklaoids," Suffness et al., pp. 73-89, copyright 1985, Academic Press, Inc.
	Wall et al., "New Type of 9-Nitrocamptothecin and a Method of its Production," J. Am. Chem. Soc., Vol. 88, No. 16, pp. 3888-3890, August 20, 1966
	Translation of Japanese Patent to Yakuruto Company, K.K.
	Hsiang, YH. et al., Cancer Res. 48: 1722-1726, 1988
	Wani, M.C. et al., J. Med. Chem. 30: 1774-1779, 1987
	Wani, M.C. et al., J. Med. Chem 29: 2358-2363, 1986
	Hsiang, YH. et al., J. Biol. Chem 97: 14873-14878, 1985
	Hsiang, YH. et al., Abstract 683 from The American Association for Cancer Research, Vol. 29, March 1988
	Wall, M.E. et al., J. Med. Chem. 29: 1553-1555, 1986
	Nelson, W.G. et al., Cancer Res. 47: 3246-3250, 1987
	Hsiang, YH. et al., Cancer Res. 49: 4386-4389, 1989
	Wani, M.C. et al., J. Med. Chem. 30: 2317-2319, 1987
	Giovanella, B.C. et al., Cancer 52: 1146-1152, 1983
	Wani, M.C. et al., J. Med. Chem. 30: 1774-1779, 1987
	Wani, M.C. et al., J. Med. Chem. 23: 554-560, 1980
	Leibovitz, A. et al., Cancer Res. 36: 4562-4569, 1976
	Fogh, J. et al., in "Human Tumor Cells In Vitro," Fogh, Jr. et., Plenum Press, New York, 1976, pp. 115-141.
	Liu, L.F. et al., Proc. Nat'l. Acad. Sci. USA, 78: 3487-3491, 1981
	Muggla, F.M. et al., Cancer Chemo. Rep. 56: 515-521, 1972

Page 5 of 10

	Gottleib, J.A. et al., Cancer Chemo. Rep. 54: 461-470, 1970
	Jaxel,C. et al., Cancer Res. 49: 1465-1469, 1989
	Potmesil, M. et al., Cancer Res. 48: 3537-3543, 1988
	Chemical Abstracts, Vol. 106(25), Abstract No. 207285z (1987)
	Chemical Abstracts, Vol. 106(15), Abstract No. 120133z (1987)
	Chemical Abstracts, Vol. 106(15), Abstract No. 11479a (1987)
	Chemical Abstracts, Vol. 106(13), Abstract No. 95753s (1987)
	Chemical Abstracts, Vol. 103(9), Abstract No. 64374c (1985)
	Chemical Abstracts, Vol. 101, Abstract No. 130677r (1984)
	Chemical Abstracts, Vol. 101(11), Abstract No. 91322z (1982)
	Chemical Abstracts, Vol. 101(10), Abstract No. 78770z (1984)
	Chemical Abstracts, Vol. 100(21), Abstract No. 167724j (1983)
	Chemical Abstracts, Vol. 100, Abstract No. 139434w (1984)
	Chemical Abstracts, Vol. 97, Abstract No. 188278b (1982)
	Chemical Abstracts, Vol. 96(9), Abstract No. 69271p (1981)
	Chemical Abstracts, Vol. 95(15), Abstract No. 133209h (1981)
	Chemical Abstracts, Vol. 94(1), Abstract No. 4143n (1980)
	Chemical Abstracts, Vol. 92(5), Abstract No. 37766e (1980)
·	Chemical Abstracts, Vol. 92(3), Abtract No. 18799b (1980)
	Chemical Abstracts, Vol. 90(4), Abstract No. 28930k (1979)
	Chemical Abstracts, Vol. 90(3), Abstract No. 22857v (1979)
	Chemical Abstracts, Vol. 84, Abstract No. 115629p (1976)
	Chemical Abstracts, Vol. 94(12), Abstract No. 90169e (1980)
	Derwent 89-179979/25
	Nicholas et al., J. Med. Chem., Vol. 33, No. 3, pp. 972-978, 1990
	Ohro et al., Proc. Ann. Meet. Am. Soc. Clin. Oncol., 8: A1019, 1989
	Hertzberg et al., J. Med. Chem., Vol. 32(3), pp. 715-720, 1989
	Hsiang et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 30: A2476, 1989

Page 6 of 10

	Hertzberg et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 30: A2485, 1989
	Pommier et al., Proc. Ann. Meet. Am. Assoc. Cancer Res., 29: A1080, 1988
	Lin et al., Yao Hsueh Hsueh Pao, Vol. 23(3), pp. 186-188 (1988)
	Ronman et al., Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 18(3), pp. 319-329, 1981
	Danishefky et al., J. Org. Chem., Vol. 39(28), pp. 3430-3432, 1974
	Plattner et al., J. Org. Chem., Vol. 39(3), pp. 303-311, 1974
	Plattner et al., J. Amer. Chem. Soc., Vol. 94(24), pp. 8615-8616, 1972
	Govindachari et al., "9-Methoxycamptothecin: a New Alkaloid from Mappie voetida Miers," pp. 453-454
	Giovanella et al., Science, Vol. 246, pp. 1046-1048, 1989
	Xi-Ran et al., "Topical Camptothecine in Treatment of Psoriasis," Int'l. Journal of Dermatology, Vol. 27, No. 7, pp. 475-476, September 1988
	Ching-jung et al., "Effect of Topical Use of Camptothecine-Dimethyl Sulfoxide Solution in Psoriasis," Chinese Medical Journal, Vol. 1, No. 5, pp. 355-360, September 1975
	Tung et al., "Camptothecin Instillation and Local Injection for Prevention and Treatment of Urinary Bladder Turnors," Chinese Medical Journal, Vol. 92, No. 1, pp. 57-60, 1979
	Pantazis et al., "Complete Inhibition of Growth Followed by Death of Human Malignant Melanoma Cells in Vitro and Regression of Human Melanoma Xenografts in Immunodeficient Mice Induced by Camptothecin," Cancer Research, Vol. 52, No. 14, pp. 3980-3987, July 15, 1992
Examiner	Date Considered

Form PTO 1449-Patent and Trademark Office - U.S. Department of Commerce

next communication to applicant.

Page 7 of 10

INFORMATION
DISCLOSURE
STATEMENT
PTO-1449

Atty. Docket No. 3603-030-03

Serial No. Not yet assigned

Applicants:

Beppino C. GIOVANELLA et al.

Filing Date: July 28, 2003 Parent Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Translation (Yes or No)
	AC	0 540 099 A1	05/05/93	European	Yes
	AD	0 418 099 A2	03/20/91	European	Yes
	AE	WO 91 05556	05/02/91	PCT	Yes
·	AF	59-46284	03/15/84	Japan	Yes
	AG	59-51287	.03/24/84	Japan	Yes
	AH	59-51288	03/24/84	Japan	Yes

OTHER DOCUMENTS

	AI	Anderson et al., Mutation Research, 309:109-142 (1994)
	AJ	Frei et al., Mutagenesis, 11(4):315-325 (1996)
	AK	Gao et al., Carcinogenesis, 17:1141-1148 (1996)
	AL	Hinz et al., Cancer Research, 54:3096-3100 (1994)
	AM	Rubin et al., J. Biological Chemistry, 269(4):2433-2439 (1994)
Examiner		Date Considered

Page 8 of 10

INFORMATION
DISCLOSURE
STATEMENT
PTO-1449

Atty.	Docket	No.	3603-	030-0	3
-------	--------	-----	-------	-------	---

Serial No. Not yet assigned

Applicants:

Beppino C. GIOVANELLA et al.

Filing Date: July 28, 2003 Parent Group Art Unit: 1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
	AA	·					
	AB					·	

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Translation (Yes or No)
AO				
 AP				
 AQ				

OTHER DOCUMENTS

	AS	Pantazis et al., Int. J. Cancer, 53:863-871 (1993)
	AT	Pantazis et al., Cancer Research, 53:1577-1582 (1991)
	AU	Tanizawa et al., J. Biological Chemistry, 268(34):25463-25467 (1993)
	AV	Verschraegen et al., Abstract 1356, Proceedings of Asco, 16:381a (1997)
	AW	Verschraegen et al., Anti-Cancer Drugs, 9:36-44 (1998)
	AX	Zhang et al., Carcinogenesis, 15:2303-2310 (1994)
Examiner		Date Considered

				Page 9	of 10			
INFORMATION DISCLOSURE STATEMENT		Atty. Docket No; 3603-030-03 Serial No. Not yet assign			assigned			
		Applicants: Beppino C. GIOVANELLA et al.						
PTO	PTO-1449		Filing I	Date: July	28,2003 Par	ent Group A	rt Unit:16	14 sign
			·	U.S. PAT	ENT DOCUME	NTS		
Examiner Initial	1	Oocum	ent No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
	AA							
	AB							
			F	OREIGN I	PATENT DOCU	MENTS		
		Docur	nent No.		Date	Country		Translation (Yes or No)
	AC	_						
	AD							
	AE							
	AF							
	AG							•
	AH							
				OTH	ER DOCUMEN	rs ·		
	AI	Car	nptotheci	et al., "Pro n". <i>The Ani</i> 1996).	tocols for the Tre	eatment of H York Academ	uman Tum y of Scienc	nor Xenografts with ces, 803:181-187
	AJ	Car	Natelson, et al., "Phase I Clinical and Pharmacological Studies of 20-(S)-Camptothecin and 20-(S)-9-Nitrocamptothecin as Anticancer Agents", The Annals of the New York Academy of Sciences, 803:181-187 (Dec. 13, 1996).					
	AK							
ll	AT	[

Examiner

 AM

Date Considered

Information Disclosure Statement U.S. Patent Application No. 10/052,294

Page 10 of 10

Applicant: GIOVANELLA, et al.				Unassigned					
• •	IOVANELLA, et al.								
Filing Date: July 28, 2003 Parent C	Group Art Unit:	1614							
U.S.	. PATENT DOC	UMENTS							
Examiner Document Date Initial* Number	Name	Class	Sub Class	Filing Date If Appropriate					
FOREI	IGN PATENT D	OCUMENTS							
Document Date Number	Country	Class	Sub Class	Translation Yes or No					
WO 93/11770 6/24/1993	WIPO	A61K	31/535						
WO 93/09782 5/27/1993	WIPO	A61K	31/535						
·									
OTHER DOCUMENTS (In	Including Author,	, Title, Date, P	ertinent Page	s, Etc.)					
Examiner	l r	Date Considere	ed.						
*Examiner: Initial if reference considered, whether of in conformance and not considered. Inc	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
Form PTO 1449		Patent and	Trademark O	ffice - U.S. Department of Commerce					